Autopsy report · NCT00548938
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
Cause of deathStaffing, sites or logistics
“Principal Investigator has left the institution”
Life of this trial
- Ran for about 3 years before it stopped.
- 40 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Methodist Healthcare - Memphis
- Sponsor type
- University, hospital or other
- Conditions
- Glioblastoma Multiforme; High-Grade Glioma
- Interventions
- Gliadel wafer; Temozolomide; External Beam Radiation Therapy
- Participants
- 40 (planned, not actual)
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
“Principal investigator left the institution” - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
“the Principal Investigator left the institution” - Prepectoral vs Partial Subpectoral Two-Stage Implant-Based Breast Reconstruction
“Principal Investigator left institution” - Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
“Original Principal Investigator left the institution.” - Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
“The original principal Investigator left the institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.